
    
      The main objective of this trial is to assess the tolerability of the up-dosing phase of
      AVANZÂ® Cupressus arizonica, the measurement rate is the frequency of patients with
      investigational medicinal product (IMP)-related adverse events (AEs) will be the primary
      endpoint.
    
  